Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01259323 | Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis | PHASE1 | COMPLETED | 30 | — | — | Dec 1, 2010 | Jul 1, 2012 | Oct 4, 2012 | 10 | United States |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN668 | BIOLOGICAL | Dose 1: REGN668 or placebo |
Inclusion Criteria: * Clinical diagnosis of atopic dermatitis that has been present for at least 3 years before the screening visit * Investigator's Global Assessment (IGA) score of \>/= 3 at the screening and baseline visits * \>/= 15% body surface area (BSA) of AD involvement at the screening and...